Product Information
AMLODIPINE-OLMESARTAN 5-20 MG is a generic product labeled by Alembic Pharmaceuticals Inc., priced at $0.2185 per EA under NDC 62332021230. Its NADAC has been published 464 times since Nov 15, 2017.
FDA first approved this application on Jul 17, 2017. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
5; 20 mg/1; mg/1
Manufacturer
Alembic Pharmaceuticals Inc.NDC
62332021230
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMILApproval Type
Generic (ANDA)
FDA Application
ANDA207073FDA Approved
7/17/2017
TE Code
AB
On Market Since
7/18/2017
Pharmacological Classes
Price Statistics
The NADAC for AMLODIPINE-OLMESARTAN 5-20 MG has been published 464 times since Nov 15, 2017, and over the history we have for it it has declined 71.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.2185 per EA |
|---|---|
| All-time high | $0.7739 (Nov 15, 2017) |
| All-time low | $0.2185 (Sep 23, 2026) |
| 52-week high | $0.2677 |
| 52-week low | $0.2185 |
| Median price | $0.4085 |
| Average price | $0.4343 |
| Largest weekly change | +64.3% (Jul 21, 2021) |
| Weeks tracked | 464 |
| Tracking since | Nov 15, 2017 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Alembic Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Amlodipine besylate and Olmesartran medoxomil market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Angiotensin 2 Receptor Blocker class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of AMLODIPINE-OLMESARTAN 5-20 MG?
The current National Average Drug Acquisition Cost (NADAC) for AMLODIPINE-OLMESARTAN 5-20 MG, manufactured by Alembic Pharmaceuticals Inc., is $0.2185 per EA (NDC 62332021230), effective Sep 30, 2026.
How has the price of AMLODIPINE-OLMESARTAN 5-20 MG changed over time?
Over the history we have for it, the NADAC for AMLODIPINE-OLMESARTAN 5-20 MG has declined 71.8%. It has been tracked across 464 weekly CMS publications since Nov 15, 2017.
What are the highest and lowest recorded NADAC prices for AMLODIPINE-OLMESARTAN 5-20 MG?
Since Nov 15, 2017, the NADAC for AMLODIPINE-OLMESARTAN 5-20 MG has ranged from a low of $0.2185 (Sep 23, 2026) to a high of $0.7739 (Nov 15, 2017), with a median of $0.4085 per EA.
Are there cheaper alternatives to AMLODIPINE-OLMESARTAN 5-20 MG?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as AMLODIPINE-OLMESARTAN 5-20 MG in a comparable dosage form, but none are currently priced below it.
Who manufactures AMLODIPINE-OLMESARTAN 5-20 MG?
AMLODIPINE-OLMESARTAN 5-20 MG (NDC 62332021230) is labeled by Alembic Pharmaceuticals Inc., and CMS classifies it as a generic product.